Little Sparrows Technologies Bili-Hut

Donna Brezinski

A battery operated tool to treat jaundice in newborns

Content Partner:

Product description Brand name and product description

The Bili-Hut™ serves as a portable and battery-operable phototherapy device to treat neonatal jaundice. It is constructed from commercially available materials and low-energy consuming LED lights with a radial light display and reflective surface for amplified light delivery and increased skin exposure.

Target region(s) Target region for distribution/implementation (listed by country if specified)

According to the 2016 WHO Compendium, the Bili-Hut is targeted for distribution in the African, Eastern Mediterranean, and South East Asia regions.

Distributors/implementing organizations Organization(s) distributing/deploying this product directly to communities/individuals?"

Not applicable. The device has not yet been commercialized and is still in the prototype/testing stage.

Market suggested retail price Price per unit or service price per usage/terms (USD). Subsidies noted.

According to the 2016 WHO Compendium, the list price of the Bili-Hut is 1500 USD per unit. However, the designer states that the device has not yet been commercialized and final cost has not been established.

Competitive landscape Similar products available on the market. May not be a comprehensive listing.

Other phototherapy solutions for treatment of neonatal jaundice. An overview includes competitors such as DtM Firefly ; Medela Bilibed, Draeger Photo-Therapy, Natus neoBLUE, Delta TL, and the D-Rev Brilliance series.

SDG targeted United Nations Sustainable Development Goals (SDGs) targeted with this product/application/service

Goal 3: to improve and promote good health.

Neonatal jaundice is caused by the accumulation of bilirubin, a breakdown product of hemoglobin in red blood cells. Approximately two-thirds of all newborns have some jaundice, giving a characteristic yellow color to the skin and eyes. Although many babies recover without any intervention, one in twelve newborns have severe jaundice requiring phototherapy treatment. If a baby with severe jaundice does not receive phototherapy in a timely manner, bilirubin may accumulate in the brain, causing permanent brain damage or even death. Severe jaundice is responsible for up to 30% of newborn deaths in many underdeveloped areas, and surviving infants are often left with permanent disabilities such as cerebral palsy, blindness, and hearing loss.

Target user(s) Target user/consumer base (country, income segment)

According to the 2016 WHO Compendium, the intended user should be trained, such as trained caregivers, midwives, technicians, nurses, and general or specialized physicians.

The @AutodeskFdn blogged about our how-to guide for communities writing proposals for development projects https://t.co/MlRH1H0x2F